RadhakrishnanRamchandrenMD

PubMed

• 1047 citations
  Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
  Anas Younes, Ajay K. Gopal, Scott E. Smith, Stephen M. Ansell, Joseph D. Rosenblatt
  Journal of Clinical Oncology. 2012-06-20
• 50 citations
  Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma
  Reid W. Merryman, Luca Castagna, Laura Giordano, Vincent T. Ho, Paolo Corradini
  Leukemia. 2021-03-03
• 242 citations
  Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma
  Margaretha G.M. Roemer, Robert A. Redd, Fathima Zumla Cader, Christine Pak, Sara Abdelrahman
  Journal of Clinical Oncology. 2018-02-02

Journal Articles

• Phase 2 Study of Everolimus for Relapsed or Refractory Classical Hodgkin Lymphoma  
  Patrick B. Johnston, Radhakrishnan Ramchandren, Lauren C. Pinter-Brown, BioMed Central

Abstracts/Posters

• Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study
  Radhakrishnan Ramchandren, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study
  Radhakrishnan Ramchandren, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Preliminary Phase 1 Data on the Safety and Efficacy of a Novel PET Radiotracer, 124I-p5+14, for Imaging Systemic Amyloidosis
  Radhakrishnan Ramchandren, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Final Results of Phase 1/1b Study of Tenalisib, Dual PI3K _/_ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma
  Radhakrishnan Ramchandren, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• North American Practice Patterns for PET-2 Positive Hodgkin Lymphoma
  Radhakrishnan Ramchandren, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Classic Hodgkin Lymphoma: Part 3 (Concurrent Dosing) Resul... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Checkpoint Blockade Therapy May Sensitize Hodgkin Lymphoma to Subsequent Therapy 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Checkpoint Blockade Therapy May Sensitize Aggressive and Indolent Non-Hodgkin Lymphoma to Subsequent Therapy 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018